TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31045534

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) with Particle Swarm Optimization (PSO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) with Genetic Algorithm (GA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support Vector Machine (SVM) without optimization
Number of subjects: 0
Study: 26552099

Group type: EXPERIMENTAL
Intervention: AllergiSense smartphone app and sensing system for injection training and feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper-only control group
Number of subjects: 0
Study: 25409596

Group type: EXPERIMENTAL
Intervention: Pexacerfont (300 mg/day for 7 days, followed by 100 mg/day for 23 days)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Open-label pexacerfont (same dosing regimen)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23994781

Group type: EXPERIMENTAL
Intervention: Tandem autologous hematopoietic stem cell transplantation (auto-HSCT) followed by reduced-intensity conditioning (RIC) and allogeneic (allo)‐HSCT with bortezomib and donor lymphocyte infusions (group 1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tandem auto-RIC-allo-HSCT without bortezomib (group 2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Matched controls for group 1
Number of subjects: 25

Group type: COMPARATOR
Intervention: Matched controls for group 2
Number of subjects: 25
Study: 21205590

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent implantation (SES)
Number of subjects: 91

Group type: COMPARATOR
Intervention: 90Sr/90Y-VBT (Control)
Number of subjects: 91
Study: 18456379

Group type: EXPERIMENTAL
Intervention: Cognitive skill learning in PD patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cognitive skill learning in healthy controls
Number of subjects: 10
Study: 21485105

Group type: EXPERIMENTAL
Intervention: hANP (0.025 microg x kg(‐1) x min(‐1))
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 39
Study: 17849195

Group type: EXPERIMENTAL
Intervention: Computer-presented automatization exercises
Number of subjects: 14

Group type: COMPARATOR
Intervention: Computer-presented exercises aimed at the use of context for word identification and comprehension
Number of subjects: 14
Study: 12127830

Group type: EXPERIMENTAL
Intervention: Appropriate care with hylan G‐F 20 (AC+H)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Appropriate care without hylan G‐F 20 (AC)
Number of subjects: 255
Study: 9445108

Group type: EXPERIMENTAL
Intervention: Endoscopic laser ablation (mean 4 sessions, energy 4709 joules)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no laser ablation, only antireflux surgery)
Number of subjects: 17
Study: 7988780

Group type: EXPERIMENTAL
Intervention: Glipizide treatment
Number of subjects: 0
Study: 2738213

Group type: EXPERIMENTAL
Intervention: Social problem-solving therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Training in the problem-orientation component
Number of subjects: 39
Study: 791320

Group type: EXPERIMENTAL
Intervention: Phenobarbitone (50 mg) 8-hourly for 3 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Orphenadrine (100 mg) 8-hourly for 3 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Chlorpromazine (100 mg) 8-hourly
Number of subjects: 17
Study: 29228144

Group type: EXPERIMENTAL
Intervention: individualized texting for adherence building (iTAB)
Number of subjects: 398

Group type: COMPARATOR
Intervention: standard care (SoC)
Number of subjects: 398
Study: 27261084

Group type: EXPERIMENTAL
Intervention: Zip surgical skin closure device
Number of subjects: 214

Group type: COMPARATOR
Intervention: Subcuticular sutures
Number of subjects: 214
Study: 25151341

Group type: EXPERIMENTAL
Intervention: Personalized RA risk education based on demographics, RA-associated behaviors, genetics, and biomarkers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard RA information
Number of subjects: 0
Study: 22476643

Group type: EXPERIMENTAL
Intervention: Heterozygosity at the D8S1179 locus
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (people over 90 years without CI)
Number of subjects: 131
Study: 20410233

Group type: EXPERIMENTAL
Intervention: Pasireotide 200-600 microg s.c. twice daily for 28 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Octreotide 100 microg s.c. three times daily for 28 days
Number of subjects: 60
Study: 18765397

Group type: EXPERIMENTAL
Intervention: Darapladib (160 mg daily)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 16059596

Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 12501878

Group type: EXPERIMENTAL
Intervention: Cefditoren 200 mg BID
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Cefditoren 400 mg BID
Number of subjects: 851

Group type: COMPARATOR
Intervention: Cefpodoxime 200 mg BID
Number of subjects: 851
Study: 10069786

Group type: EXPERIMENTAL
Intervention: Patients with OSA during hypoxia
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patients with OSA during hypoxia with apnea
Number of subjects: 28
Study: 8524980

Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) 1.5 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) 2.5 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (DZP) 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (DZP) 10 mg
Number of subjects: 0
Study: 2261347

Group type: EXPERIMENTAL
Intervention: IFN plus melphalan plus prednisone (IFN-MP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: melphalan plus prednisone (MP)
Number of subjects: 50
Study: 35214

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alcohol + Clobazam 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Clobazam alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Alcohol + Placebo
Number of subjects: 8
Study: 30821640

Group type: EXPERIMENTAL
Intervention: Personal value orientation: self-enhancement value
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personal value orientation: self-transcendence value
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Value-invoking message: invoked
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Value-invoking message: non-invoked
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Freedom threat: high
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Freedom threat: low
Number of subjects: 0
Study: 28240597

Group type: COMPARATOR
Intervention: PR (pegylated interferon + ribavirin) for 24-48 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TVR (telaprevir) + PR for 12-24 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TVR + PR
Number of subjects: 34
Study: 25733676

Group type: EXPERIMENTAL
Intervention: Hypnotic medication as an add-on treatment to a selective serotonin reuptake inhibitor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo as an add-on treatment to a selective serotonin reuptake inhibitor
Number of subjects: 40
Study: 22897785

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with cow's milk protein increased from 0.06 mg to a maximum of 6400 mg over 23 weeks.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo group (control) receiving no active treatment.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall long-term success rate of OIT.
Number of subjects: 28
Study: 21898715

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: SSRI (escitalopram)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Combination of interpersonal psychotherapy and SSRI
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 225
Study: 19375019

Group type: EXPERIMENTAL
Intervention: Titanium plate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Absorbable plate
Number of subjects: 23
Study: 16835599

Group type: EXPERIMENTAL
Intervention: Endurance Trained (ET)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Moderately Trained (MT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sedentary (SE)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All groups (SE, MT, ET)
Number of subjects: 34
Study: 14522732

Group type: EXPERIMENTAL
Intervention: Corn Flakes (CF)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bran Cereal (BC)
Number of subjects: 6
Study: 10889153

Group type: COMPARATOR
Intervention: r-metHuBDNF (100 microg/kg SC daily for 2 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: r-metHuNT-3 (300 microg/kg SC thrice weekly for 2 weeks)
Number of subjects: 56
Study: 8742566

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1560424

Group type: EXPERIMENTAL
Intervention: Informed group (awareness of elevated blood pressure)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (invited to coronary heart disease prevention program)
Number of subjects: 32
Study: 3904336

Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 11
Study: 30118582

Group type: EXPERIMENTAL
Intervention: IV acetaminophen (1 g) + IV hydromorphone (0.5 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (100 mL normal saline) + IV hydromorphone (0.5 mg)
Number of subjects: 81
Study: 29152847

Group type: EXPERIMENTAL
Intervention: brexpiprazole + antidepressant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo + antidepressant therapy
Number of subjects: 0
Study: 26731172

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Positive Psychotherapy (PPT)
Number of subjects: 54
Study: 24709364

Group type: EXPERIMENTAL
Intervention: Pro‐Self(©) Plus Pain Control Program
Number of subjects: 0
Study: 22362849

Group type: EXPERIMENTAL
Intervention: Urine Determine(TM) TB-LAM point-of-care strip-test using microbiological reference standard with grade-1 cut-off point
Number of subjects: 423
Study: 20032026

Group type: EXPERIMENTAL
Intervention: Experimental approach (insertion point 3 cm lateral to the midpoint of ischial tuberosity)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional approach (prone subgluteal approach)
Number of subjects: 39
Study: 17510577

Group type: EXPERIMENTAL
Intervention: Individual psychosocial support by specially trained oncology nurses
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Individual psychosocial support by psychologists
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 179
Study: 16103770

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted protease inhibitor regimens (lopinavir, indinavir, saquinavir, amprenavir at 50%, 32%, 11%, and 6% respectively)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: NIQ (normalized inhibitory quotient) derived from Cmin/FC
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Fold change (FC) and trough drug concentration (Cmin)
Number of subjects: 87
Study: 11855668

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/day, p.o.) for 3 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study: 9720999

Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) technique with bipolar surface electrodes
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Visual feedback on isometric force impulses
Number of subjects: 29
Study: 8606538

Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg once daily (n = 16)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lisinopril 20 mg once daily (n = 20)
Number of subjects: 36
Study: 2526717

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate + EE (monophasic)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Desogestrel + EE (monophasic)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Gestodene + EE (triphasic)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study: 268331

Group type: EXPERIMENTAL
Intervention: Sorbitol flavoured gum
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sucrose flavoured gum
Number of subjects: 24

Group type: COMPARATOR
Intervention: No oral hygiene and no chewing (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sorbitol flavoured gum (chewed 10 pieces for 3 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sucrose flavoured gum (chewed 10 pieces for 3 hours)
Number of subjects: 24
Study: 30635021

Group type: EXPERIMENTAL
Intervention: Change score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post score
Number of subjects: 0
Study: 29581519

Group type: EXPERIMENTAL
Intervention: 8-week online mindfulness intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: internet-delivered psychoeducation
Number of subjects: 67
Study: 27881518

Group type: EXPERIMENTAL
Intervention: Healthy Habits for Life intervention (printed materials plus a personally tailored discussion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 24731674

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet or exercise or both)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 577
Study: 22466022

Group type: EXPERIMENTAL
Intervention: Exercise + attention training (EX + AMP)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Rest + attention training (REST + AMP)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Exercise + attention control condition (EX + ACC)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Rest + attention control condition (REST + ACC)
Number of subjects: 112
Study: 18617572

Group type: EXPERIMENTAL
Intervention: Presence of a friend
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of a peer
Number of subjects: 0
Study: 17460332

Group type: EXPERIMENTAL
Intervention: Caffeinated sports drink (CES+CAF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte sports drink (CES)
Number of subjects: 16
Study: 15249998

Group type: EXPERIMENTAL
Intervention: Birmingham Hip Resurfacing (BHR) for primary osteoarthritis
Number of subjects: 88

Group type: COMPARATOR
Intervention: Birmingham Hip Resurfacing (BHR) for secondary osteoarthritis due to dysplasia
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Birmingham Hip Resurfacing (BHR) for both groups
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Birmingham Hip Resurfacing (BHR) for dysplastic hips
Number of subjects: 88
Study: 11258648

Group type: EXPERIMENTAL
Intervention: 400 microg b.i.d. (group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 200 microg b.i.d. (group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment (group C)
Number of subjects: 36
Study: 10050994

Group type: EXPERIMENTAL
Intervention: Cs-137 uterovaginal application followed by surgery (either immediate or delayed)
Number of subjects: 204
Study: 8290186

Group type: EXPERIMENTAL
Intervention: 20-minute regimen for labor induction
Number of subjects: 1801

Group type: COMPARATOR
Intervention: 40-minute regimen for labor induction
Number of subjects: 1801

Group type: EXPERIMENTAL
Intervention: 20-minute regimen for labor augmentation
Number of subjects: 1801

Group type: COMPARATOR
Intervention: 40-minute regimen for labor augmentation
Number of subjects: 1801
Study: 3142593

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 1494489

Group type: EXPERIMENTAL
Intervention: Oxytocin (18 IU per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxytocin (3-fold higher dosage)
Number of subjects: 12
Study: 152602

Group type: EXPERIMENTAL
Intervention: Muscimol treatment
Number of subjects: 10
Study: 31450958

Group type: EXPERIMENTAL
Intervention: Protocols available
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Statistical analysis plans available
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Protocols in 20% random sample
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: A priori protocols in 20% random sample
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Statistical analysis plans in 20% random sample
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: A priori statistical analysis plans in 20% random sample
Number of subjects: 365
Study: 30616657

Group type: EXPERIMENTAL
Intervention: 1000 mg of ferric carboxymaltose (single dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 200 g/48 h of iron sucrose (fractionated doses)
Number of subjects: 48
Study: 28239907

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 1200 mg/day
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 26318714

Group type: EXPERIMENTAL
Intervention: IPV-bOPV-bOPV
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: IPV-IPV-bOPV
Number of subjects: 570

Group type: COMPARATOR
Intervention: IPV-IPV-IPV
Number of subjects: 570
Study: 24210705

Group type: EXPERIMENTAL
Intervention: Monitoring and Reporting (MR)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Monitoring Alone (MA)
Number of subjects: 253
Study: 23115399

Group type: EXPERIMENTAL
Intervention: Short sleep (4 hr in bed)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Habitual sleep (9 hr in bed)
Number of subjects: 27
Study: 19485842

Group type: EXPERIMENTAL
Intervention: Biomarker-guided treatment strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional test-guided treatment strategies
Number of subjects: 0
Study: 17691581

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at 80 Hz, 2.5 mA for 30 min, once every other day for 2 months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Hydroxyl-chloroquine (6 mg/kg per day), oral transfer agent liquid, Vit B1, Vit B2, Vit C, fish-liver oil, and pilocarpine (20 mg/d) for 2 months
Number of subjects: 57
Study: 15381891

Group type: EXPERIMENTAL
Intervention: Virtual reality distraction intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-virtual reality distraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual without distraction
Number of subjects: 0
Study: 11433050

Group type: EXPERIMENTAL
Intervention: Sn-mesoporphyrin (SnMP) administered as a single intramuscular dose of 6 micromol/kg birth weight within 24 +/- 12 hours of age
Number of subjects: 340

Group type: COMPARATOR
Intervention: G‐6‐PD‐normal newborns (control group)
Number of subjects: 340

Group type: COMPARATOR
Intervention: G‐6‐PD‐deficient newborns (comparison group)
Number of subjects: 340
Study: 9851653

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7736844

Group type: EXPERIMENTAL
Intervention: Oesophagectomy without thoracotomy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Oesophagectomy via right thoracotomy and midline incision
Number of subjects: 96
Study: 2591459

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 10
Study: 5297557

Group type: EXPERIMENTAL
Intervention: Danish BCG vaccine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Swedish BCG vaccine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Czechoslovak BCG vaccine
Number of subjects: 3
Study: 31655974

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg every 4 weeks or 12 weeks)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 30042075

Group type: EXPERIMENTAL
Intervention: Stable emulsion
Number of subjects: 812

Group type: COMPARATOR
Intervention: Unstable emulsion
Number of subjects: 812
Study: 27021193

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 1276

Group type: COMPARATOR
Intervention: CTC
Number of subjects: 1276
Study: 24842175

Group type: EXPERIMENTAL
Intervention: Flexible tracheoscope
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Video laryngoscope plus flexible tracheoscope
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (preformed stylet)
Number of subjects: 140
Study: 22334228

Group type: EXPERIMENTAL
Intervention: Diet and Metformin 1000 mg/day (D+M)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Diet, Metformin 500 mg/day and MYO 4 g/day plus 400 µg folic acid daily (D+M+I)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Diet alone (D)
Number of subjects: 27
Study: 21102966

Group type: EXPERIMENTAL
Intervention: Thoracic medial branch blocks with bupivacaine (Group I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thoracic medial branch blocks with bupivacaine and non-particulate betamethasone (Group II)
Number of subjects: 100
Study: 18569916

Group type: EXPERIMENTAL
Intervention: Mupirocin applied once a week (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mupirocin applied three times a week (n = 18)
Number of subjects: 36
Study: 15750189

Group type: EXPERIMENTAL
Intervention: 600-mg clopidogrel loading dose
Number of subjects: 255

Group type: COMPARATOR
Intervention: 300-mg clopidogrel loading dose
Number of subjects: 255
Study: 12356779

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein diet (approximately 90 mg of total isoflavones/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isoflavone-deficient soy protein diet
Number of subjects: 28
Study: 10856150

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg twice daily (FP100BID)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg once daily (FP200QD)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study: 8857869

Group type: EXPERIMENTAL
Intervention: Structured depression treatment program including behavioral treatment and counseling
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Structured depression treatment program
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care by primary care physicians
Number of subjects: 153